Aurora Diagnostics to Offer Assay to Aid in the Selection of TECENTRIQ™ Therapy in Lung Cancer
LAS VEGAS – LMC Pathology Services, an Aurora Diagnostics specialty practice in Las Vegas, Nevada, was selected by Ventana Medical Systems, a Roche Diagnostics Company, as one of the first pathology groups in the United States to begin providing VENTANA’s PD-L1 (SP142) Assay. This complementary assay is an immunohistochemical tissue stain corresponding with the release of Genentech’s TECENTRIQ™ (atezolizumab). The Food and Drug Administration (FDA) approved TECENTRIQ™ October 18, 2016 for the treatment of advanced non-small cell lung cancer (NSCLC).
Genentech’s TECENTRIQ™ (atezolizumab, anti-PDL1; MPDL3280A) is an anti-programmed death ligand-1 (PD-L1) immunotherapy for the treatment for people with locally advanced or metastatic NSCLC who exhibit disease progression. NSCLC accounts for 85 percent of all lung cancers in the U.S., where the American Cancer Society estimates there will be 224,390 new cases of lung cancer in 2016.
Ventana PD-L1 (SP142) Assay is intended for use in the assessment of PD-L1 protein in NSCLC tissue. Determination of PD-L1 status is indication-specific, and evaluation is based on a FDA-approved scoring algorithm. Stains are scored by a pathologist using manual microscopy following an FDA-approved protocol. PD-L1 expression determined by Ventana’s assay in NSCLC tissue may be associated with enhanced overall survival from TECENTRIQ™.
“This is a revolutionary breakthrough in managing the personalized treatment of patients with lung cancer,” said Joel S. Bentz, MD, FCAP the Medical Director of Aurora Diagnostics LMC Pathology Services. “Our practice is honored to be one of a handful in the country that will be performing this assay, and our pathologists look forward to assisting our clients in interpreting the results as they plan treatments for their patients.”
“Aurora Diagnostics and the Aurora Research Institute provided services that accelerated the approval of this important complementary diagnostic test,” said Michael Null, President of Aurora Research Institute. “We are excited to be at the forefront of personalized medicine.”
About Aurora Diagnostics
Aurora Diagnostics is a leading independent pathology services and cancer diagnostics company, offering integrated diagnostic and personalized medicine consultations and information technology solutions to physicians and hospital systems. Our pathologists provide diagnostic opinions and work collaboratively with referring physicians to determine appropriate patient treatment options. We also provide services to pharmaceutical companies and other research entities to support their efforts to develop new cancer treatments.
Aurora Diagnostics operates 26 community-based pathology practices with over 160 board-certified pathologists. We provide services to a broad array of physician specialists, including dermatologists, obstetricians and gynecologists, family practitioners, gastroenterologists, urologists, general surgeons and oncologists. Aurora also serves as laboratory medical director for more than 360 laboratory sites across the country, including 90 hospital clients.
Our client-centric approach to providing diagnostic services is driven by our belief that the practice of medicine and the delivery of healthcare are both personal and best delivered locally. With our extensive pathology expertise, we are able to support comprehensive integrated approaches to patient care. For additional information regarding Aurora Diagnostics, please visit www.auroradx.com.